

Sponsored by:



In partnership with the:



**Controlling the HIV Epidemic with Antiretrovirals: Treatment as Prevention and Pre-Exposure Prophylaxis**  
11-12 June 2012 • Royal Garden Hotel, London

<b>11-Jun-12</b>	
<b>0800-0815</b>	<b>Welcome by Conference Co-Hosts</b> <i>José M. Zuniga, PhD, MPH* (IAPAC), Jane Anderson, PhD* (BHIVA)</i>
	<b>Welcome by Conference Co-Chairs</b> <i>Brian Gazzard, MD* (Chelsea &amp; Westminster Hospital), Kenneth Mayer, MD* (Harvard University)</i>
<b>0815-0845</b>	<b>Keynote Address: Combination Prevention - Public Health and Human Rights Imperatives</b> <i>Gottfried Hirnschall, MD* (WHO)</i>
<b>Treatment as Prevention (TasP)</b>	
<b>0845-0930</b>	<b>Panel 1: Review of Current TasP Studies</b> <b>Moderator:</b> <i>Papa Salif Sow, MD* (University of Dakar)</i> <i>Victor De Gruttola, ScD* (Harvard University)</i> <i>Sarah J. Fidler, MBBS, PhD* (Imperial College, London)</i>
<b>0930-0950</b>	<b>Plenary 1: Perspectives from the Vancouver TasP Workshop</b> <i>Julio Montaner, MD* (University of British Columbia)</i>
<b>0950-1035</b>	<b>Panel 2: Facilitating Access to TasP from Bench to Clinic</b> <b>Moderator:</b> <i>Mauro Schechter, MD* (Federal University of Rio de Janeiro)</i> <i>Michael Norton, MPAS* (Abbott Laboratories)</i> <i>John Pottage, MD* (ViiV Healthcare)</i> <i>Jim Rooney, MD* (Gilead Sciences)</i> <i>Paul Schaper* (Merck &amp; Co.)</i>
<b>1035-1135</b>	<b>Discussion</b>
<b>1135-1205</b>	<b>Coffee Break</b>

1205-1225	<b>Plenary 2: TasP - Individual versus Public Health Benefit versus Both</b> <i>Paul Kasonkomona* (OXFAM Civil Society Health Forum, Lusaka, Zambia)</i>
1225-1245	<b>Plenary 3: Health System Concerns Related to TasP and MARPs</b> <i>Valerie Delpech, MD, MPH* (UK Health Protection Agency)</i>
1245-1305	<b>Discussion</b>
1305-1405	<b>Lunch</b>
1405-1450	<b>Panel 3: Implementing TasP - Addressing Clinical and Other Concerns</b> <b>Moderator:</b> <i>Bertrand Audoin* (International AIDS Society)</i> <i>Ceri Evans* (Chelsea &amp; Westminster Hospital) - protocols, surveillance</i> <i>Gus Cairns* (European AIDS Treatment Group) - community perspective</i> <i>Ian Williams, MD* (University College London) - adherence, resistance</i> <i>Robert Carroll, RN* (Association of Nurses in AIDS Care) - health workforce perspective</i> <i>Jorge Saavedra, MD* (AIDS Healthcare Foundation) - treatment coverage, impact evaluation</i>
1450-1510	<b>Plenary 5: Cost-Benefit Analysis of Universal versus Incremental TasP</b> <i>Bernard Schwartzlander, MD* (UNAIDS)</i>
1510-1530	<b>Plenary 6: Ethical Standards vis-à-vis Prevention in Biomedical Prevention Trials</b> <i>Richard Ashcroft, PhD* (Queen Mary University of London)</i>
1530-1630	<b>Discussion</b>
1630-1715	<b>Panel 4: Implementing Universal TasP - Wishful Thinking?</b> <b>Moderator:</b> <i>Nikos Dedes* (Positive Voice, Athens, Greece)</i> <i>Eric Fleutelot* (Sidaction) - human rights considerations</i> <i>Peter Cherutich, MD, MPH* (National AIDS/STD Control Program, Kenya) - budgetary constraints</i> <i>Helen Rees, MD* (University of Witwatersrand, South Africa) - public health considerations</i>
1715-1815	<b>Discussion</b>
1830-2030	<b>Opening Reception</b>

<b>12-Jun-12</b>	
<b>Pre-Exposure Prophylaxis (PrEP)</b>	
0800-0820	<b>Plenary 7: PrEP - Current Global Themes and Future Directions</b> <i>Kenneth Mayer, MD* (Harvard University)</i>
0820-0840	<b>Plenary 8: Antiretroviral Pharmacology for PrEP</b> <i>Craig Hendrix, MD* (Johns Hopkins University)</i>

0840-0925	<p><b>Panel 5: Review of Current PrEP Studies</b></p> <p><b>Moderator:</b> <i>Carmen Zorilla, MD* (University of Puerto Rico)</i>  <i>Roy M. Gulick, MD* (Cornell University)</i>  <i>Sheena McCormack, MSc* (UK Medical Research Council)</i>  <i>Ian McGowan, MD, PhD* (University of Pittsburgh)</i>  <i>Bruno Spire, MD, PhD* (INSERM, U912, Marseille)</i></p>
0925-0955	<b>Coffee Break</b>
0955-1040	<p><b>Panel 6: Facilitating Access to PrEP from Bench to Clinic</b></p> <p><b>Moderator:</b> <i>Chris Duncombe, MD, PhD* (Gates Foundation)</i>  <i>Jim Rooney, MD* (Gilead Sciences)</i>  <i>Ron d'Amico, MD* (Abbott Laboratories)</i>  <i>Manuel Goncalves* (ViiV Healthcare)</i>  <i>Paul Schaper* (Merck &amp; Co.)</i></p>
1040-1140	<b>Discussion</b>
1140-1200	<p><b>Plenary 9: Behavior and PrEP - Risk Compensation and Other Concerns</b></p> <p><i>K. Rivet Amico, PhD* (University of Connecticut)</i></p>
1200-1220	<p><b>Plenary 10: Managing PrEP-Related Safety Concerns</b></p> <p><i>Veronica Miller, PhD* (Forum for Collaborative HIV Research)</i></p>
1220-1240	<p><b>Plenary 11: Cost-Benefit Analysis of Universal versus Selective PrEP</b></p> <p><i>Bruce Schackman, PhD* (Weill Cornell Medical College)</i></p>
1240-1410	<b>Lunch</b>
1410-1455	<p><b>Panel 7: Community, Provider, Operational, and Regulatory Perspectives on PrEP Implementation</b></p> <p><b>Moderator:</b> <i>Yuzef Azad* (National AIDS Trust, United Kingdom)</i>  <i>Claire Foreman* (London HIV Consortium) - access, cost from public sector payor</i>  <i>Michael Horberg, MD* (Kaiser Permanente) - access, cost from private sector payor</i>  <i>Benjamin Young, MD, PhD* (IAPAC) - workforce</i>  <i>Jim Pickett* (AIDS Foundation of Chicago) - community</i>  <i>EMEA representative - approval, surveillance</i></p>
1455-1555	<b>Discussion</b>
1555-1625	<b>Coffee Break</b>
<b>TasP and PrEP</b>	
1625-1645	<b>Plenary 12: IAPAC Adherence Guidelines - Addressing the Achilles' Heel of TasP and PrEP</b>

	<i>Jean Nachega, MD, PhD* (Johns Hopkins University/Stellenbosch University)</i>
<b>1645-1705</b>	<b>Plenary 13: Implementation Science - Building the <u>Prevention 2.0</u> Ship As We Sail Her</b> <i>Kevin Fenton, MD, PhD* (US CDC)</i>
<b>1705-1725</b>	<b>Plenary 14: Combination Prevention - Seizing the Moment to Curb an Pandemic</b> <i>José M. Zuniga, PhD, MPH* (IAPAC)</i>
<b>1725-1800</b>	<b>Rapporteur Session &amp; Closing Remarks</b>

*\* Confirmed as of 22 May 2012*